CORPORATE INFO
FOR INVESTORS
OUR PRODUCTS
BUSINESS DEVELOPMENT
CONTACT US
HOME
Menu
Financial Statements
Financial Reports
Securities Filing
Investor Resources
Fact Sheet
Presentations
Analyst Coverage
Calendar of Events
FAQ
Shareholder
Services
Investor Kit
Investor Information
News
Press Releases
Corporate News
Awards
PRESS RELEASES
COMMUNIQUÉS DE PRESSE (Français)
2013
|
2012
|
2011
|
2010
|
2009
|
2008
|
2007
|
2006
|
2005
|
2004
|
2003
|
2002
|
2001
|
2000
|
1999
|
1998
|
1997
|
December 17, 2012
PALADIN LABS ANNOUNCES CANADIAN APPROVAL FOR SILENOR
(Also in
PDF
format)
December 12, 2012
PALADIN LABS SIGNS AGREEMENT FOR EMTRIX IN CANADA
(Also in
PDF
format)
November 20, 2012
PALADIN LABS ANNOUNCES THE CANADIAN LAUNCH OF ORALAIR(TM)
(Also in
PDF
format)
November 19, 2012
PALADIN ANNOUNCES INITIATION OF LATIN AMERICAN COMMERCIAL FOOTPRINT
(Also in
PDF
format)
November 13, 2012
PALADIN REPORTS RECORD THIRD QUARTER 2012 RESULTS
(Also in
PDF
format)
November 6, 2012
NOTICE OF PALADIN LABS' THIRD QUARTER 2012 RESULTS CONFERENCE CALL
(Also in
PDF
format)
October 18, 2012
PALADIN LABS TO PRESENT AT THE TD SECURITIES 2012 SMALL CAP CONFERENCE IN TORONTO
(Also in
PDF
format)
October 18, 2012
PALADIN ANNOUNCES AGREEMENT FOR NOVEL OTC PRODUCT TO TREAT COLD SORES
(Also in
PDF
format)
October 9, 2012
PALADIN ANNOUNCES AGREEMENT WITH QRXPHARMA FOR NOVEL ACUTE PAIN PRODUCT
(Also in
PDF
format)
August 2, 2012
PALADIN REPORTS SECOND QUARTER 2012 RESULTS-INCREASES 2012 REVENUE GUIDANCE TO OVER $200 MILLION
(Also in
PDF
format)
July 26, 2012
NOTICE OF PALADIN LABS' SECOND QUARTER 2012 RESULTS CONFERENCE CALL
(Also in
PDF
format)
July 3, 2012
PALADIN LABS COMPLETES STRATEGIC PARTNERSHIP TRANSACTION WITH LITHA
(Also in
PDF
format)
June 22, 2012
LITHA COMPLETES REGISTRATION OF SPECIAL RESOLUTIONS REQUIRED IN CONNECTION WITH PALADIN'S STRATEGIC INVESTMENT
(Also in
PDF
format)
June 14, 2012
PALADIN LABS TO PRESENT AT THE BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE IN TORONTO
(Also in
PDF
format)
June 6, 2012
LITHA SHAREHOLDERS VOTE TO APPROVE STRATEGIC INVESTMENT BY PALADIN LABS
(Also in
PDF
format)
June 4, 2012
PALADIN LABS INC.: TRAVELAN(R) MARKET APPROVAL APPLICATION ACCEPTED FOR REVIEW BY HEALTH CANADA
(Also in
PDF
format)
May 31, 2012
PALADIN LABS TO PRESENT AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN NEW YORK
(Also in
PDF
format)
May 30, 2012
PALADIN LABS TO PRESENT AT THE NATIONAL BANK FINANCIAL CONFERENCE IN MONTREAL
(Also in
PDF
format)
May 29, 2012
PALADIN LABS INC. NAMES JONATHAN ROSS GOODMAN AS CHAIRMAN OF THE BOARD OF DIRECTORS
(Also in
PDF
format)
May 28, 2012
PALADIN LABS AND NUVO RESEARCH SIGN CANADIAN LICENSE AGREEMENT FOR SYNERA AND A LOAN AGREEMENT
(Also in
PDF
format)
May 3, 2012
PALADIN REPORTS FIRST QUARTER 2012 RESULTS ACHIEVES RECORD REVENUES
(Also in
PDF
format)
April 26, 2012
NOTICE OF PALADIN LABS' FIRST QUARTER 2012 RESULTS CONFERENCE CALL
(Also in
PDF
format)
March 21, 2012
PALADIN LABS ANNOUNCES CANADIAN APPROVAL FOR ORALAIR(TM)
(Also in
PDF
format)
February 22, 2012
PALADIN AND SOMAXON ANNOUNCE FILING OF NEW DRUG SUBMISSION FOR SILENOR(R)
(Also in
PDF
format)
February 21, 2012
PALADIN TO PRESENT AT THE RBC CAPITAL MARKETS HEALTHCARE CONFERENCE IN NEW YORK CITY
(Also in
PDF
format)
February 21, 2012
PALADIN ANNOUNCES STRATEGIC PARTNERSHIP WITH LITHA AND MERGING OF SOUTH AFRICAN PHARMACEUTICAL BUSINESSES
(Also in
PDF
format)
February 16, 2012
PALADIN REPORTS SIXTEENTH CONSECUTIVE YEAR OF RECORD REVENUES
(Also in
PDF
format)
February 9, 2012
NOTICE OF PALADIN LABS' FOURTH QUARTER 2011 RESULTS CONFERENCE CALL
(Also in
PDF
format)
HOME
|
SITE MAP
|
LEGAL DISCLAIMER
